Cell Reports:阿尔兹海默症治疗方法或可发生改变

2015-05-28 佚名 生物谷

老年痴呆症患者大脑的一个典型特征是存在不溶性的Tau蛋白质总量。鲁汶大学和杨森制药公司的科学家已经证明,这些Tau蛋白质总量的分布可促进大脑细胞之间的突触连接。这个消息非常重要,因为越来越多的关注集中在修复突触连接上,该方向可作为一种治疗神经退行性疾病如阿尔茨海默氏症的方法。事实上,人们普遍认为突触连接的断失会导致认知能力的丧失。Dieder Moechars(杨森制药公司)说:“从研究结果分析来

老年痴呆症患者大脑的一个典型特征是存在不溶性的Tau蛋白质总量。鲁汶大学和杨森制药公司的科学家已经证明,这些Tau蛋白质总量的分布可促进大脑细胞之间的突触连接。这个消息非常重要,因为越来越多的关注集中在修复突触连接上,该方向可作为一种治疗神经退行性疾病如阿尔茨海默氏症的方法。事实上,人们普遍认为突触连接的断失会导致认知能力的丧失。

Dieder Moechars(杨森制药公司)说:“从研究结果分析来看,我们建议谨慎进行突触的修复治疗方法。我们的研究表明,突触也促进Tau蛋白总量的分布,这样可能会阻碍突触修复的积极作用。同样重要的是开发新的治疗策略时应考虑到一点,如突触修复应与突触中清除Tau蛋白总量相结合。”

Patrik Verstreken(鲁汶大学)说:“我们专门为这一研究建立了一个新的体外系统,该系统能促进典型的神经退行性疾病总蛋白质在整个大脑的分布。我们也想使用这个系统来探索可以阻止大脑神经退行性变的药物,而在实验早期阶段不必使用动物模型。这可能成为寻找例如阿尔茨海默氏症的潜在药物的一个重要工具。

脑细胞突触通过突触交流。成功的突触连接对大脑正常运行至关重要。突触变性是一个典型的神经退行性疾病,如阿尔茨海默氏症的症状。阿尔茨海默氏症患者因神经突触的损失而导致认知能力的下降。这就是为什么许多研究集中在如何治疗突触的修复。

而正在研究这项内容的科学家们发现要实现这种方法并非易事。Sara Calafate说:“我们注意到,Tau总蛋白的传播是阿尔茨海默氏症的一个典型特征,通过脑细胞的互相连接使Tau总蛋白的传播变得更有效力。但目前仍不清楚这一过程中突触的作用。在这个方法中,我们已设法证明突触可促进这种蛋白分布,也可以促进神经退行性变。”

科学家开发出的体外模型研究工具帮助研究人员观察到Tau总蛋白扩散的同时改变了脑细胞间的突触连接。研究人员也观察到突触连接时比没有突触连接时Tau总蛋白的分布效率要高出50%。

Patrik Verstreken说:“我们研究脑部疾病没有动物模型是不可能的。然而我们不断在寻找可以减少动物实验数量的方法。而这个新工具可以帮助我们实现这一目标。”

原始出处:

Sara Calafate, Arjan Buist, Katarzyna Miskiewicz, Vinoy Vijayan, Guy Daneels, Bart de Strooper, Joris de Wit, Patrik Verstreken, Diederik Moechars.Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation.Cell Reports, May 26, 2015.DOI: http://dx.doi.org/10.1016/j.celrep.2015.04.043

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2016-02-21 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-05-31 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-05-28 Dr.LV

    有法子治就好啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869126, encodeId=e1d51869126a3, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 10 23:01:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959380, encodeId=e9781959380f9, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Feb 21 02:01:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25566, encodeId=7fff2556645, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:13:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399181, encodeId=a3551399181f1, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402655, encodeId=ae6c140265552, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 30 07:01:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25216, encodeId=d91025216cc, content=有法子治就好啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Dr.LV, createdTime=Thu May 28 21:39:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25204, encodeId=16fa2520421, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Thu May 28 16:22:00 CST 2015, time=2015-05-28, status=1, ipAttribution=)]
    2015-05-28 summer474cn

    期待

    0

相关资讯

Nature Neuroscience:脑低糖的摄取似乎加剧阿尔茨海默病

据来自南加州大学医学院的凯克学院(USC)一项新的小鼠研究,在负责整个大脑的保护血脑屏障运输葡萄糖的蛋白缺乏会产生加大阿尔茨海默氏病的神经退行性影响。 该研究表明,靶向GLUT1蛋白可能有助于预防或减缓阿尔茨海默氏症的影响,尤其是那些处于危险的疾病。这项名为“GLUT1减少加剧阿尔茨海默氏症血管—神经功能障碍和变性”的研究发表在《自然神经科学》杂志上。 该研究的主要研究者、凯克医学院Zilkh

清华施一公院士PNAS再发突破性成果

人们普遍认为,阿尔茨海默病(俗称老年痴呆)主要起因于β淀粉样蛋白(Aβ)在大脑内的累积。γ-分泌酶可以切割β淀粉样前体蛋白生成Aβ,与阿尔茨海默病的发病密切相关,是预防和治疗这种疾病的潜在靶点,受到了研究者们的广泛关注。γ分泌酶的切割过程非常复杂,这与它的复杂结构和作用机制有关。与组分单一的其他膜蛋白不同,γ分泌酶包含四种组分:presenilin (PS1)、Pen-2、Aph-1和Nicast

J Neurosci:研究发现阿尔茨海默病潜在新病因

来自杜克大学的研究团队在国际期刊神经学杂志上发表了他们的研究发现。研究人员使用一种具有更接近人免疫系统的阿尔茨海默病小鼠,以便观察疾病早期的免疫变化。研究者发现应用一种小分子药物可以阻碍免疫细胞消耗精氨酸。在小鼠身上测试发现,它避免了出现神经斑和记忆消失等阿尔茨海默病特征。他们阐述他们的发现点不仅是新的阿尔茨海默病潜在病因,也是新的治疗靶点。来自杜克大学医学院的神经学家,资深作者Carol Col

JAMDA:AD患者使用美金刚胺好处多?MAIN-AD试验结果说:不见得

背景:阿尔茨海默病(AD)患者相应的神经精神症状会引起他们明显而又强烈的痛苦,同时患者面临的是复杂的治疗措施,这已成为巨大挑战。若使用药物治疗,则医生对抗精神病药物的选择是有限的,并且使用抗精神病药物有广泛的安全问题。目前有证据支持美金刚胺治疗AD的潜在好处,并且该药物在AD患者中重度神经精神症状的治疗已经获得使用许可。研究方式:该研究采用双盲随机安慰剂对照抗精神病药物美金刚胺在超过24周的时间里

阿尔茨海默病治疗获重大突破,超声技术显神效

当你不再记得回家的路,不再记得孩子的名字,不再记得爱人的样貌,不再记得上一刻自己正在做的事,甚至不再记得怎么样作为“普通人”生活……你会怎样面对这个世界?去年,电影《依然爱丽丝》将阿尔茨海默病 (Alzheimer's disease,AD)病人的生活搬上了大银幕。这种被简称为“AD”的疾病是全球发病率最高的一种神经退行性疾病,正一刻不停地夺走着“爱丽丝”们的记忆、生活能力乃至生命。AD:一直

PNAS:卒中药物依达拉奉或可防治阿尔茨海默病

第三军医大学大坪医院神经内科王延江教授课题组与澳大利亚南澳大学(UniSA)Xin-Fu Zhou教授课题组合作,在PNAS上发表研究,报道了临床上用于急性缺血性卒中的药物依达拉奉具有防治阿尔茨海默病(Alzheimer’s disease,AD)的作用。 AD是一种以进行性、不可逆的记忆力减退和认知功能障碍为主要表现的神经退行性疾病,是最常见的痴呆。目前全球范围有AD患者大概有3650万,预计